Best joint supplements to ease arthritis pain in 2025, according to experts
However, it's important to stay grounded in the facts: Supplements for arthritis and joint pain aren't magic bullets, and their effectiveness can vary from person to person. "There isn't much evidence-based universal support for any arthritis supplement," says Dr. Leia Rispoli, a double-board-certified interventional pain management specialist and physiatrist at DISC Sports & Spine Center.
Still, if you're curious to see whether a supplement could help soothe aches and pains — and your doctor has given you the green light to do so — some supplements may be worth a try. To help you navigate your options, we spoke with five health care professionals, including three dietitians and two doctors, then reviewed top products based on formulation, ingredient quality, cost and tester feedback. Read on to discover the five best joint supplements to discuss with your doctor at your next appointment.
Best arthritis and joint pain supplements for 2025
Factors to consider when shopping for joint supplements
How we chose
FAQs on natural remedies for arthritis and joint pain
Meet our experts
A note on supplements
The products included on this list are dietary supplements. Statements about these products have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. Dietary supplements are not appropriate for everyone and may interact with other supplements or medications, so talk to your health care provider before adding a dietary supplement to your routine.
According to dietitian Jamie Lee McIntyre, omega-3 fatty acid supplements — including fish oil — are among the most researched and effective options for helping ease both rheumatoid- and osteoarthritis-related pain and inflammation. "Omega-3s (especially EPA and DHA) have natural anti-inflammatory properties. They work by decreasing the production of inflammatory chemicals (like prostaglandins and cytokines) that contribute to joint pain and stiffness in conditions like rheumatoid arthritis and osteoarthritis," she says.
A group of studies looked into how omega-3 fatty acid supplements might help people with osteoarthritis, and found that taking omega-3 supplements significantly reduced arthritis pain and improved joint function compared to a placebo.
For targeting joint pain and inflammation, McIntyre recommends looking for a fish or algal oil supplement with at least 1,000 mg of combined EPA and DHA omega-3s. To ensure label accuracy, she also says it's best to choose a product that's third-party tested for purity and potency. An easy way to check for this is by looking for an NSF or International Fish Oil Standards (IFOS) certification on the product's packaging.
(back to top)
Turmeric is a golden-yellow spice often used in cooking and has long been used as a natural remedy to help reduce inflammation and ease aching joints. In particular, its main active component — curcumin — is well known in the wellness sphere for its potent antioxidant and anti-inflammatory properties. "Curcumin reduces inflammation by blocking pro-inflammatory cytokines and scavenging free radicals that damage cells," says Vanessa Imus, a dietitian and owner of Integrated Nutrition for Weight Loss in Bothell, Wash.
Like many supplements used for arthritis, more large-scale, high-quality studies are needed to fully confirm turmeric's benefits. That said, the existing research is promising. One review found that turmeric supplements were linked to significant improvements in both pain and physical function among people with knee osteoarthritis. Interestingly, in three studies where turmeric was compared to nonsteroidal anti-inflammatory drugs (NSAIDs), turmeric supplements performed just as well.
Another review, which analyzed 29 studies, also found encouraging results, with turmeric supplementation associated with reduced pain severity across five types of arthritis — including ankylosing spondylitis, rheumatoid arthritis, osteoarthritis, juvenile idiopathic arthritis and gout. It's worth noting that effective doses ranged from 120 mg to 1500 mg daily, so you'll want to talk with a health care professional about the best starting dose for your needs.
Expert tip: As a dietitian myself, I know that turmeric on it's own isn't well-absorbed by the body. Luckily, pairing it with black pepper extract (piperine) or oil — like in a liposomal supplement formulation — can help.
(back to top)
Glucosamine and chondroitin are naturally occurring compounds in cartilage — the tissue that cushions joints. These supplements have become increasingly popular for people with osteoarthritis, as they may help slow the breakdown of cartilage. But despite their popularity, research supporting their effectiveness is mixed. For instance, one review found that people taking a combination of glucosamine and chondroitin scored better on a key arthritis test compared to those taking placebos. However, for other measures, like pain scores, the results were less clear or not significant.
Research currently suggests an effective dose of 1,500 mg of glucosamine and 1,200 mg of chondroitin. However, because studies on the subject are mixed, it's best to talk with a health care professional about if and how much glucosamine and chondroitin to take.
It's also important to note that glucosamine and chondroitin aren't safe or appropriate for everyone, including those with shellfish allergies, asthma, diabetes, prostate cancer, glaucoma or those taking anticoagulant medications (like warfarin).
(back to top)
Collagen plays a crucial role in maintaining healthy joints and may be especially beneficial for those managing arthritis. Found naturally in the body, collagen is a protein that helps build cartilage to support smooth, pain-free movement. With arthritis, cartilage can break down over time, leading to pain, stiffness and inflammation. While more research is needed, taking collagen supplements may help replenish the body's natural supply and support joint health, potentially reducing discomfort and improving mobility.
Research suggests that taking hydrolyzed collagen supplements — aka supplements where collagen is broken down into smaller pieces that are more readily digested and absorbed — may stimulate the production of new cartilage and reduce joint pain over time. Plus, collagen is easy to incorporate into your routine, whether through powders, capsules or collagen-rich foods like bone broth.
(back to top)
Vitamin D plays a vital role in both immune function and bone health, and not getting enough of this sunshine vitamin may be contributing to your aches and pains. While those already meeting their vitamin D needs may not see additional benefits, one review found that adults with arthritis and widespread pain were more likely to have insufficient vitamin D levels. In a smaller study, adults with knee osteoarthritis who hadn't undergone knee surgery experienced modest improvements in knee pain over five years if they took vitamin D regularly and maintained adequate levels for at least two years.
Beyond supporting joint and bone health, adequate vitamin D intake has also been linked to other benefits for healthy aging, including a reduced risk of falls and chronic disease. The optimal dose to support arthritis and joint pain ultimately depends on your current vitamin D status, with higher doses often necessary for those with a confirmed deficiency.
(back to top)
'Before adding any supplement to your routine, its important to talk with your doctor or a qualified health care provider for personalized guidance. Once you've done that, keep these key factors in mind when choosing the best arthritis supplement:
Manufacturer reputation: Choose brands with a strong reputation for quality and transparency.
Third-party testing: Look for supplements that are independently tested for purity and potency to ensure you're getting what the label claims.
Ingredient transparency: Opt for supplements with clear labeling and minimal fillers or additives.
Research-backed ingredients and dosage: While research into supplements for arthritis and joint pain is still evolving, some ingredients are supported by stronger evidence than others. When evaluating a product, in addition to clinically-backed ingredients, check for doses that have been shown to be effective in research.
Other active ingredients: It's important to be aware that some supplements touted as being beneficial for arthritis — like red yeast rice, chaparral and cat's claw — aren't well-supported by research and may be dangerous when taken regularly. While some ingredients, like vitamin D, may be safe and even helpful for joint pain, make sure you're not already getting them from another supplement, like your multivitamin or protein powder.
Medication interactions: Always check with a health care professional before taking any new supplements to ensure they wont interact with prescription or over-the-counter medications you're currently taking.
Dietary restrictions: If you have allergies or other dietary preferences or restrictions, make sure to carefully read the ingredient list to choose a supplement that aligns with your needs.
Price: High-quality supplements are available at a variety of price points. While it's important not to sacrifice quality for cost, the most expensive option isn't always the best one either.
(back to top)
To identify the best supplements for arthritis and joint pain, we conducted an in-depth review of the most up-to-date research and consulted medical professionals and dietitians to understand which ingredients are most effective — and which ones to avoid.
For specific product recommendations, we combined these expert insights with hands-on tester feedback, prioritizing formulations backed by scientific evidence and real-world experience. The result: a list of supplements that are both research-supported and user-approved.
(back to top)
Research on supplements for joint pain is limited, and the best supplement for arthritis depends on your specific symptoms and health needs. Fish oil, turmeric and collagen are among the most well-researched options. It's a good idea to talk with a health care professional to determine which supplement may work best for you.
Green tea may be helpful for those managing arthritis thanks to its impressive antioxidant profile — including epigallocatechin gallate (EGCG), a compound with potent anti-inflammatory effects. Tart cherry juice may also be beneficial, with some studies linking it to improvements in pain and overall quality of life among those with knee osteoarthritis. That said, one of the best ways to support joint health is by staying hydrated.
Rispoli says an overall healthy lifestyle is key for managing arthritis pain. She highlights eating a balanced diet, maintaining a healthy weight, managing stress and engaging in non-impact exercise, like yoga or swimming, as being particularly helpful. She also notes the importance of understanding your symptoms, advising to "[Get] educated on what pains might be more severe than normal."
Amidor agrees that diet plays a significant role in managing joint pain. She points out that certain foods may be particularly helpful thanks to their anti-inflammatory benefits. These include fatty fish (like salmon and tuna), nut, seeds, olive oil and berries.
CBD (cannabidiol) has gained attention for its potential to relieve pain and reduce inflammation. "Some people have reported relief with CBD locally," says Dr. Nora Singer, director of the Division of Rheumatology at MetroHealth.
"CBD [may] help arthritis pain because there's usually a natural anti-inflammatory component and maybe a menthol or lidocaine component which distracts some of the nerves from feeling pain," says Rispoli. Still, it's important to note that CBD isn't safe or effective for everyone, and it's crucial to exercise caution by purchasing only from reputable, well-vetted manufacturers.
When it comes to arthritis, research on NAD+ is promising, but ultimately scarce. NAD+ (nicotinamide adenine dinucleotide) is a tiny but mighty molecule found in every cell of your body, helping to keep things running smoothly. One of its many roles is helping to repair your DNA and support your body as it fights off damage over time. However, as we age, the levels of NAD+ naturally decrease, which can make us more prone to issues like inflammation and other age-related health problems.
While NAD+ may have potential therapeutic benefits for arthritis and joint pain thanks to its role in reducing inflammation and promoting cellular repair, there's currently a lack of human studies to support its effectiveness.
"Taking a warm bath or shower to get moving can be helpful and can help lubricate stiff joints," says Singer. She also suggests paraffin wax hand treatments for patients with hand stiffness and avoiding prolonged immobilization.
(back to top)
Leia Rispoli, double-board-certified interventional pain management specialist and physiatrist at DISC Sports & Spine Center in Southern California
Jamie Lee McIntyre, MS, RDN, nutrition consultant
Vanessa Imus, MS, RDN, dietitian and owner of Integrated Nutrition for Weight Loss in Bothell, Wash.
Toby Amidor, MS, RD, award-winning nutrition expert
Nora Singer, director of the division of rheumatology at MetroHealth and professor of medicine and pediatrics at Case Western Reserve University School of Medicine
(back to top)
Our health content is for informational purposes only and is not intended as professional medical advice. Consult a medical professional on questions about your health.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 minutes ago
- Yahoo
BioXcel Therapeutics Announces Positive FDA Pre-sNDA Meeting Comments for sNDA Submission for BXCL501 in Agitation Associated with Bipolar Disorders or Schizophrenia
Achieved alignment with the FDA on sNDA package to expand the IGALMI label for the At-Home (Outpatient) setting sNDA submission on track for Q1 2026 NEW HAVEN, Conn., Aug. 18, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that it has received positive pre-sNDA meeting responses from the U.S. Food and Drug Administration (FDA). Based on the FDA's feedback, the Company believes that the planned sNDA regulatory package will be sufficient to support the sNDA submission, which remains on track for the first quarter of 2026. The primary purpose of the planned meeting was to gain alignment with the FDA regarding the content and format of the Company's planned supplemental New Drug Application (sNDA) submission for the at-home (outpatient) use of BXCL501, including the clinical, nonclinical, and chemistry and manufacturing and controls (CMC) requirements. The Company concludes that the objectives of the pre-sNDA meeting have been accomplished based on the FDA's written responses and has determined that the meeting, originally scheduled for August 20, 2025, is no longer required. The pre-sNDA preliminary meeting comments received from FDA on August 14, 2025, will serve as the official record. Acceptance of the sNDA will be subject to the FDA's review of the complete filing. 'We are pleased with the pre-sNDA meeting feedback we received from the FDA, which confirmed agreement on the content and format for our planned sNDA submission, and reflects a shared commitment to addressing the urgent needs of patients living with bipolar disorder or schizophrenia,' said Vimal Mehta, Ph.D., CEO of BioXcel Therapeutics. 'This marks an important milestone in our mission to bring a safe and effective outpatient treatment to patients suffering from agitation, potentially transforming the treatment paradigm.' IGALMI is currently FDA-approved and marketed for the acute treatment of agitation associated with bipolar I or II disorder or schizophrenia in medically supervised settings. IGALMI is available in 2 dose strengths, 120 mcg and 180 mcg. To support the potential label expansion for at-home use, an important part of the regulatory package will be data from the pivotal Phase 3 SERENITY At-Home trial, which is a double-blind, placebo-controlled 12-week study designed to evaluate the safety of a 120 mcg dose of BXCL501 for the acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home setting. The trial design and protocol were agreed with FDA at a Type C Meeting held in March 2024. The Company recently announced the completion of the last patient last visit (LPLV), with topline data expected this month. BXCL501 was granted Fast Track Designation for the acute treatment of agitation associated with bipolar disorders or schizophrenia. There are no FDA-approved therapies for the acute treatment of agitation in the at-home setting. About the SERENITY At-Home Phase 3 Trial The SERENITY At-Home Phase 3 trial is a double-blind, placebo-controlled study designed to evaluate the safety of a 120 mcg dose of BXCL501 for the acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home setting. The trial is designed to evaluate 200 patients with a history of agitation episodes residing at home either alone or with caregivers/informants. Patients are self-administering 120 mcg of BXCL501 or placebo when agitation episodes occur over the 12-week trial period, with safety data (adverse events) collected during the trial. In addition, patients or caregivers/informants complete a modified global impression of severity (mCGIs) and a clinical global impression of change (mCGI-C) two hours after dosing as an exploratory endpoint to evaluate use in the outpatient setting. About BXCL501Outside of its approved indication by the U.S. Food and Drug Administration as IGALMI® (dexmedetomidine) sublingual film, BXCL501 is an investigational proprietary, orally dissolving film formulation of dexmedetomidine, a selective alpha-2 adrenergic receptor agonist. BXCL501 is under investigation by BioXcel Therapeutics for the acute treatment of agitation associated with Alzheimer's dementia and for the acute treatment of agitation associated with bipolar I or II disorder or schizophrenia in the at-home setting. The safety and efficacy of BXCL501 for these investigational uses have not been established. BXCL501 has been granted Breakthrough Therapy designation by the FDA for the acute treatment of agitation associated with dementia and Fast Track designation for the acute treatment of agitation associated with schizophrenia, bipolar disorders, and dementia. About IGALMI® (dexmedetomidine) sublingual filmINDICATION IGALMI® (dexmedetomidine) sublingual film is a prescription medicine, administered under the supervision of a health care provider, that is placed under the tongue or behind the lower lip and is used for the acute treatment of agitation associated with schizophrenia and bipolar disorder I or II in adults. The safety and effectiveness of IGALMI has not been studied beyond 24 hours from the first dose. It is not known if IGALMI is safe and effective in children. IMPORTANT SAFETY INFORMATION IGALMI can cause serious side effects, including: Decreased blood pressure, low blood pressure upon standing, and slower than normal heart rate, which may be more likely in patients with low blood volume, diabetes, chronic high blood pressure, and older patients. IGALMI is taken under the supervision of a healthcare provider who will monitor vital signs (like blood pressure and heart rate) and alertness after IGALMI is administered to help prevent falling or fainting. Patients should be adequately hydrated and sit or lie down after taking IGALMI and instructed to tell their healthcare provider if they feel dizzy, lightheaded, or faint. Heart rhythm changes (QT interval prolongation). IGALMI should not be given to patients with an abnormal heart rhythm, a history of an irregular heartbeat, slow heart rate, low potassium, low magnesium, or taking other drugs that could affect heart rhythm. Taking IGALMI with a history of abnormal heart rhythm can increase the risk of torsades de pointes and sudden death. Patients should be instructed to tell their healthcare provider immediately if they feel faint or have heart palpitations. Sleepiness/drowsiness. Patients should not perform activities requiring mental alertness, such as driving or operating hazardous machinery, for at least 8 hours after taking IGALMI. Withdrawal reactions, tolerance, and decreased response/efficacy. IGALMI was not studied for longer than 24 hours after the first dose. Physical dependence, withdrawal symptoms (e.g., nausea, vomiting, agitation), and decreased response to IGALMI may occur if IGALMI is used longer than 24 hours. The most common side effects of IGALMI in clinical studies were sleepiness or drowsiness, a prickling or tingling sensation or numbness of the mouth, dizziness, dry mouth, low blood pressure, and low blood pressure upon standing. These are not all the possible side effects of IGALMI. Patients should speak with their healthcare provider for medical advice about side effects. Patients should tell their healthcare provider about their medical history, including if they suffer from any known heart problems, low potassium, low magnesium, low blood pressure, low heart rate, diabetes, high blood pressure, history of fainting, or liver impairment. They should also tell their healthcare provider if they are pregnant or breastfeeding or take any medicines, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Patients should especially tell their healthcare provider if they take any drugs that lower blood pressure, change heart rate, or take anesthetics, sedatives, hypnotics, and opioids. Everyone is encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088. You can also contact BioXcel Therapeutics, Inc. at 1-833-201-1088 or medinfo@ Please see full prescribing information at About BioXcel Therapeutics, Therapeutics, Inc. (Nasdaq: BTAI) is a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience. Its wholly owned subsidiary, OnkosXcel Therapeutics, is focused on the development of medicines in immuno-oncology. The Company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indications. For more information, please visit Forward-Looking Statements This current report includes 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this current report other than statements of historical fact should be considered forward-looking statements, including, without limitation, statements related to: the Company's upcoming top-line data release for the SERENITY At-Home Phase 3 trial, the planned sNDA submission, bringing a safe and effective outpatient treatment to patients suffering from agitation and transforming the treatment paradigm. When used herein, words including 'anticipate,' 'believe,' 'can,' 'continue,' 'could,' 'designed,' 'estimate,' 'expect,' 'forecast,' 'goal,' 'intend,' 'may,' 'might,' 'plan,' 'possible,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' 'would' and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon the Company's current expectations and various assumptions. The Company believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. The Company may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation: its limited operating history; its incurrence of significant losses; its need for substantial additional funding and ability to raise capital when needed; the impact of the reprioritization; its significant indebtedness, ability to comply with covenant obligations and potential payment obligations related to such indebtedness and other contractual obligations; the conditions and events that raise substantial doubt about its ability to continue as a going concern; its limited experience in drug discovery and drug development; risks related to the TRANQUILITY program; its dependence on the success and commercialization of IGALMI™, BXCL501, BXCL502, BXCL701 and BXCL702 and other product candidates; the number of episodes of agitation and the size of the Company's total addressable market may be overestimated, and approval that the Company may obtain may be based on a narrower definition of the patient population; its lack of experience in marketing and selling drug products; the risk that IGALMI or the Company's product candidates may not be accepted by physicians or the medical community in general; the Company still faces extensive and ongoing regulatory requirements and obligations for IGALMI; the failure of preliminary data from its clinical studies to predict final study results; failure of its early clinical studies or preclinical studies to predict future clinical studies; its ability to receive regulatory approval for its product candidates; its ability to enroll patients in its clinical trials; undesirable side effects or potential of misuse of the Company's product candidates that could impact regulatory approval; its novel approach to the discovery and development of product candidates based on EvolverAI or our AI platform; the significant influence of and dependence on BioXcel LLC; failure to maintain compliance with Nasdaq's listing standards; its exposure to patent infringement lawsuits; its reliance on third parties; its ability to comply with the extensive regulations applicable to it; impacts from data breaches or cyber-attacks, if any; risks associated with the increased scrutiny relating to environmental, social and governance (ESG) matters; risks associated with federal, state or foreign health care 'fraud and abuse' laws; and its ability to commercialize its product candidates, as well the factors discussed under the caption 'Risk Factors' in its most recent Quarterly Report on Form 10-Q, as such factors may be updated from time to time in its other filings with the SEC. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this current report. While the Company may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this current report. Contact Information Corporate/InvestorsRusso PartnersNic MediaRusso Partners David 1.858.717.2310 Source: BioXcel Therapeutics, Inc. IGALMI® is a registered trademark of BioXcel Therapeutics, Inc. References Data on file relating to agitation episodes associated with schizophrenia or bipolar I or II disorder. BioXcel Therapeutics, Inc. New Haven, CT December 2020. Episode estimations may not reflect potential treatable episodes, and actual addressable market may be smaller. Data from Wu EQ, Shi L, Birnbaum H, et al. Annual prevalence of diagnosed schizophrenia in the USA: a claims data analysis approach. Psychol Med. 2006;36(11):1535-1540. Estimates based on whether indications are approved for at-home use for the intended patient population and such patients are treatable. Episode estimations may not reflect potential treatable episodes, and actual addressable market may be smaller. National Institute of Mental Health. Prevalence of bipolar disorder in adults. November 2017. Accessed December 16, 2022. Episode estimations may not reflect potential treatable episodes, and actual addressable market may be in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
12 minutes ago
- Yahoo
PECA Labs' Dr. Arush Kalra Named to Pittsburgh's 40 Under 40 List
Biomedical innovator recognized for advancing next-generation cardiovascular devices and making a lasting impact on patients' lives PITTSBURGH, August 18, 2025--(BUSINESS WIRE)--PECA Labs, a medical device company redefining the field of vascular grafts and valves with durable, polymeric cardiovascular devices designed to fit, grow, and last, today announced that Co-founder and Chief Scientific Officer Dr. Arush Kalra has been named to the Pittsburgh 40 Under 40 list by Pittsburgh Magazine and PUMP. The Pittsburgh 40 Under 40 awards honor high-performing, high-impact professionals who are driving innovation and strengthening the Pittsburgh community through leadership, professional excellence, and service. Dr. Kalra leads PECA Labs' scientific and engineering programs, overseeing clinical research and the development of its proprietary tunable polymeric material platform for cardiovascular implants. Inspired by his mother's battle with cardiovascular disease, he began his career in medicine before pivoting to medical device innovation at the encouragement of a mentor. While pursuing his Master of Science in Biomedical and Medical Engineering at Carnegie Mellon University (CMU), he co-founded PECA Labs with fellow CMU Tartans Doug Bernstein and Jamie Quinterno—without whom, he notes, the venture would not have been possible—to advance the field of cardiothoracic surgery. Since 2018, Dr. Kalra has also served as an adjunct professor at the University of Pittsburgh. "This recognition carries profound meaning, as it brings much-needed attention to the challenges faced by families confronting congenital cardiac defects and chronic adult cardiovascular diseases," said Dr. Kalra. "Our mission is simple yet powerful: to develop innovative cardiovascular devices that provide patients with an improved quality of life and the chance to grow, thrive, and avoid repeat surgeries. It is an honor to be recognized alongside so many talented individuals who are making a meaningful impact in the Pittsburgh community—a place that has given so much to us at PECA Labs and continues to inspire our work." In 2024, PECA Labs opened a new polymeric processing facility near its headquarters in Pittsburgh's Bloomfield neighborhood, adjacent to UPMC Children's Hospital. This expansion brings critical manufacturing in-house, giving the company greater control over production, faster scalability, and the ability to meet growing demand. About PECA Labs PECA Labs is reimagining the field of vascular grafts and valves with durable polymeric cardiovascular devices designed to fit, grow, and last—helping patients avoid repeat surgeries while reducing morbidity and mortality. The company's proprietary technologies, including a controllably expandable graft and low-thrombosis polymeric membrane, are built on a tunable polymer platform that delivers greater durability, customization, and biocompatibility than current cardiovascular implants. PECA's devices resist thrombosis, calcification, and immune response, while offering growth potential, customization, and noninvasive visualization. For more information, visit View source version on Contacts Media Contact: Joe DuraesPazanga Health Communicationsjduraes@ (917) 687-6419
Yahoo
12 minutes ago
- Yahoo
In a Major Win for Vanda, a Federal Appeals Court Overturns FDA's Order Denying Approval of Hetlioz for the Treatment of Jet Lag Disorder
WASHINGTON, Aug. 18, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that it secured a landmark victory over the U.S. Food and Drug Administration (FDA) in its longstanding dispute with the agency regarding the approvability of HETLIOZ® (tasimelteon) to treat jet lag disorder (Vanda Pharmaceuticals Inc. v. FDA, case no. 24-1049). Vanda submitted its supplemental New Drug Application (sNDA) in October 2018 to market HETLIOZ® to treat jet lag disorder. After the FDA substantially delayed resolving Vanda's request for a hearing with respect to this application, a federal district court found that the FDA "violated" the requirements of the Food, Drug, and Cosmetic Act, and the court ordered the FDA to finally resolve Vanda's sNDA or commence a hearing (Vanda Pharmaceuticals Inc. v. FDA, No. 22-cv-2775-CJN). The FDA did not commence a hearing. It instead granted summary judgment to itself and issued an order refusing to approve the sNDA. The FDA took the position that it could essentially disregard the voluminous factual evidence Vanda had presented to it. Vanda thus filed a petition for review with the U.S. Court of Appeals for the D.C. Circuit (the Court). In a sweeping win for Vanda, the Court set aside the FDA's action. The Court explained that Vanda provided expert views that were "specific, reasoned, and rooted in evidence" and that the FDA's "treatment of Vanda's evidence is cursory." In particular, the Court stated that Vanda "clearly offered meaningful evidence of tasimelteon's efficacy in improving sleep disturbance" and, further, that each of its trials "showed statistically significant improvement on the primary endpoint measured." This decision significantly alters the relationship between the FDA and the parties it regulates. The Court's holding establishes that the FDA must meaningfully engage with the evidence presented by drug innovators, and the FDA may not shield its decisions via a plea for deference. The Court has remanded the case back to the FDA, where Vanda anticipates the FDA will either approve the sNDA or Vanda will receive a hearing. This is an outstanding development for all those who suffer from jet lag. Vanda has spent more than a decade undertaking innovative clinical studies, now published in peer-reviewed journals, developing HETLIOZ® so that jet lag sufferers may finally have access to a meaningful therapeutic.1 2 3 4 Whether for an athlete, a business traveler, a government official, a tourist, or rapidly deployed troops, HETLIOZ® has the potential to fundamentally change the landscape of circadian resetting during transmeridian global travel. This is a treatment that Americans want and need. Ultimately, this decision requires that the FDA act fairly when evaluating scientific evidence. The FDA's decisions regarding new drug applications are enormously consequential. Innovators like Vanda labor to bring novel therapeutics to Americans who suffer from unmet medical needs. Improper denials by the FDA deprive the public of access to potentially life-changing medication. The Court's decision establishes that the FDA must now actually engage with the evidence presented to it. The Court's decision confirms Vanda's efforts to challenge unlawful actions by the FDA. For too long, drug manufacturers failed to exercise their rights to lawful treatment by the FDA. Vanda has demonstrated how courts can set aside illegal government actions that harm innovation and deprive Americans of important new therapeutics. Vanda looks forward to further demonstrating that HETLIOZ® should be approved to treat jet lag disorder. References Rajaratnam, S., Polymeropoulos, M., Fisher, D., Roth, T., Scott, C., Birznieks, G., Klerman, E. Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomised controlled multicentre trials. Lancet 2009; 373(9662):482-91. See also Cardinali, D., Golombek, D. Let there be sleep—on time. Ibid. 439-41. Polymeropoulos, C., Mohrman, M., Keefe, M., Brzezynski, J., Wang, J., Prokosch, L., Polymeropoulos, V., Xiao, C., Birznieks, G., Polymeropoulos, M. Efficacy of Tasimelteon (HETLIOZ®) in the Treatment of Jet Lag Disorder Evaluated in an 8-h Phase Advance Model; a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. Front Neurol. 2020; 11:611. Polymeropoulos, C., Polymeropoulos V., Cziesler, E., Fisher, M., Smieszek, S., Xiao, C., Birznieks, G., Polymeropoulos, M. Once-daily tasimelteon (VEC-162) for jet lag following transmeridian travel: A multicenter, randomized, double-blind, placebo-controlled trial. Front Neurol. 2022; 13:901467. See also Arendt, J. Approaches to the Pharmacological Management of Jet Lag. Drugs 2018;78(14):1419–1431. About Vanda Pharmaceuticals Inc. Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit and follow us on X @vandapharma. About HETLIOZ® For full U.S. Prescribing Information for HETLIOZ®, including indication and Important Safety Information, visit CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS Various statements in this press release, including, but not limited to statements regarding Vanda's prospects for receiving approval of HETLIOZ® or a hearing following the FDA's further review of the sNDA following remand, the potential of HETLIOZ® to address the needs of travelers suffering from jet lag disorder and the anticipated future behavior of the judiciary, are "forward-looking statements" under the securities laws. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Forward-looking statements are based upon current expectations and assumptions that involve risks, changes in circumstances and uncertainties. Important factors that could cause actual results to differ materially from those reflected in Vanda's forward-looking statements include, among others, the outcome of the FDA's further review of the sNDA, the ability of HETLIOZ® to fundamentally change the landscape of circadian resetting during transmeridian global travel, and the willingness of other courts to set aside the actions of the FDA. Therefore, no assurance can be given that the results or developments anticipated by Vanda will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Vanda. Forward-looking statements in this press release should be evaluated together with the various risks and uncertainties that affect Vanda's business and market, particularly those identified in the "Cautionary Note Regarding Forward-Looking Statements", "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Vanda's most recent Annual Report on Form 10-K, as updated by Vanda's subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the U.S. Securities and Exchange Commission, which are available at All written and verbal forward-looking statements attributable to Vanda or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. Vanda cautions investors not to rely too heavily on the forward-looking statements Vanda makes or that are made on its behalf. The information in this press release is provided only as of the date of this press release, and Vanda undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Corporate Contact:Kevin MoranSenior Vice President, Chief Financial Officer and Treasurer Vanda Pharmaceuticals Inc.202-734-3400pr@ Jim Golden / Jack Kelleher / Dan MooreCollected StrategiesVANDA-CS@ View original content to download multimedia: SOURCE Vanda Pharmaceuticals Inc.